Author(s):
Dessika Rahmawati, Diah Prabawati Retnani, Rose Khasana Dewi, Arvidareyna Panca Aprilianingtyas
Email(s):
dessikasps@ub.ac.id
DOI:
10.52711/0974-360X.2025.00777 
Address:
Dessika Rahmawati1,2*, Diah Prabawati Retnani3,4, Rose Khasana Dewi3,4, Arvidareyna Panca Aprilianingtyas1,2
1Department of Neurology, Saiful Anwar General Hospital, Malang, Indonesia.
2Department of Neurology, Faculty of Medicine – Universitas Brawijaya, Malang, Indonesia.
3Department of Anatomical Pathology, Saiful Anwar General Hospital, Malang, Indonesia.
4Department of Anatomical Pathology, Faculty of Medicine – Universitas Brawijaya, Malang, Indonesia.
*Corresponding Author
Published In:
Volume - 18,
Issue - 11,
Year - 2025
ABSTRACT:
Gliomas are among the most common and aggressive primary brain tumors, with prognosis influenced by histological grade and molecular characteristics. Isocitrate Dehydrogenase (IDH) mutations, particularly in IDH1 and IDH2, are critical biomarkers providing valuable prognostic and therapeutic insights. However, local data on glioma molecular profiles in Indonesia remain limited. This study aims to profile IDH mutation status in glioma patients treated at RSUD Dr. Saiful Anwar, Malang, from 2018 to 2024, and to examine its correlation with demographic characteristics, tumor histology, and WHO grading. A descriptive observational study was conducted, analyzing 31 glioma patients. Retrospective data on age, sex, tumor type, IDH status, and WHO grading were collected from medical records. Descriptive statistics were applied to determine the prevalence and distribution of IDH mutations. The cohort included 16 females (52%) and 15 males (48%), with a mean age of 52.35 years. Glioblastoma was the most common tumor type (65%), followed by astrocytoma (35%). IDH mutations were identified in 16% of cases, while 58% were IDH wild-type, linked to more aggressive behavior. Non-specific IDH status was found in 26% of patients. Most tumors (52%) were WHO Grade IV. This study underscores the critical role of IDH mutations in glioma classification and management. Molecular profiling enhances diagnostic precision and guides personalized treatment strategies. Integrating molecular diagnostics into routine practice is vital for advancing precision oncology, particularly in resource-limited settings. Future research should focus on expanding molecular testing and exploring innovative therapies to improve patient outcomes.
Cite this article:
Dessika Rahmawati, Diah Prabawati Retnani, Rose Khasana Dewi, Arvidareyna Panca Aprilianingtyas. Molecular Profiling of Isocitrate Dehydrogenase (IDH) Mutations in Gliomas: Insights from a Tertiary Referral Center in Indonesia. Research Journal Pharmacy and Technology. 2025;18(11):5389-4. doi: 10.52711/0974-360X.2025.00777
Cite(Electronic):
Dessika Rahmawati, Diah Prabawati Retnani, Rose Khasana Dewi, Arvidareyna Panca Aprilianingtyas. Molecular Profiling of Isocitrate Dehydrogenase (IDH) Mutations in Gliomas: Insights from a Tertiary Referral Center in Indonesia. Research Journal Pharmacy and Technology. 2025;18(11):5389-4. doi: 10.52711/0974-360X.2025.00777 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-11-39
REFERENCES:
1. Franceschi E, de Biase D, Pession A, Tosoni A, Paccapelo A, Visani M, et al. Survival outcomes in glioma patients with noncanonical IDH mutations: Beyond diagnostic improvements. J Clin Oncol. 2019. doi:10.1200/JCO.2019.37.15_SUPPL.2028
2. Ren F, Zhao Q, Huang L, Zheng Y, Li L, He Q, et al. The R132H mutation in IDH1 promotes the recruitment of NK cells through CX3CL1/CX3CR1 chemotaxis and is correlated with a better prognosis in gliomas. Immunol Cell Biol. 2019; 97. doi:10.1111/imcb.12225
3. Pappula AL, Rasheed S, Mirzaei G, Petreaca RC. A genome-wide profiling of glioma patients with an IDH1 mutation using the Catalogue of Somatic Mutations in Cancer database. Cancers (Basel). 2021; 13. doi:10.3390/cancers13174299
4. Juratli T, Zolal A, Stasik S, Pietzsch M, Eisenhofer G, Linn J, et al. IDH mutation prediction in glioma: A multimodal approach. Neuro Oncol. 2019. doi:10.1093/neuonc/noz175.547
5. Gondim DD, Gener M, Curless KL, Cohen-Gadol A, Hattab E, Cheng L. Determining IDH mutational status in gliomas using IDH1-R132H antibody and polymerase chain reaction. Appl Immunohistochem Mol Morphol. 2019; 27(10): 722-5. doi:10.1097/PAI.0000000000000702
6. Pan T, Su C, Tang W, Lin J, Lu S, Hong X. Combined texture analysis of dynamic contrast-enhanced MRI with histogram analysis of diffusion kurtosis imaging for predicting IDH mutational status in gliomas. Acta Radiol. 2023; 64(12): 2552-60. doi:10.1177/02841851231180291
7. Choi Y, et al. Fully automated hybrid approach to predict the IDH mutation status of gliomas via deep learning and radiomics. Neuro Oncol. 2020. doi:10.1093/neuonc/noaa177
8. Sahu P, Pinkalwar N, Dubey RD, Paroha S, Chatterjee S, Chatterjee T. Biomarkers: an emerging tool for diagnosis of a disease and drug development. Asian J Res Pharm Sci. 2011; 1(1): 9-16.
9. Dhakad GG, Shirsat SP, Tambe KP. Review on immuno-oncology agents for cancer therapy. Res J Pharmacol Pharmacodyn. 2022; 14(1): 47-52.
10. Nath L, Choudhury U, Lahkar M. A study about the pattern of adverse effects of various oncology drugs in a tertiary care hospital of North East India. Res J Pharmacol Pharmacodyn. 2022; 14(4): 208-12.
11. Kotelevets S, Chekh S, Karakotova Z. Modern possibilities of the use of non-invasive serological biomarkers severe in population studies. Res J Pharm Technol. 2019; 12(9): 4274-82.
12. Boralkar A, Bobhate P, Khairnar A. Prospective cross-sectional study in evaluation of prescribing pattern of doctors for oncology treatment. Res J Pharm Technol. 2011; 4(4): 634-7.
13. Agustina R, Lesmana R, Zakiyah N, Zahrah SN. The utilization of biomarkers in stress-related diseases. Liver. 2024; 16: 17.
14. Swapnaa B, Kumar SV. Personalized medicine—a novel approach in cancer therapy. Res J Pharm Technol. 2017; 10(1): 341-5.
15. Mirfendereski S, Shabani A, Rostamzadeh A, Fatehi D. Molecular imaging using by diffusion-weighted imaging of brain tumor through signal intensity: progress in molecular cancer imaging. Res J Pharm Technol. 2017; 10(6): 1767-71.
16. Pagar KR, Mahale MR. A review on brain tumour, etiology and treatment. Asian J Pharm Res. 2023; 13(1): 51-4.
17. Dubey A, Singh Y. Medicinal properties of Cinchona alkaloids—a brief review.
18. Berger T, Wen P, Lang-Orsini M, Chukwueke U. World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review. JAMA Oncol. 2022. doi:10.1001/jamaoncol.2022.2844
19. Richardson T, Kumar A, Xing C, Hatanpaa K, Walker JM. Overcoming the Odds: Toward a Molecular Profile of Long-Term Survival in Glioblastoma. J Neuropathol Exp Neurol. 2020;79(10):1031-7. doi:10.1093/jnen/nlaa102
20. Molinari E, Curran OE, Grant R. Clinical importance of molecular markers of adult diffuse glioma. Pract Neurol. 2019; 19: 412-6. doi:10.1136/practneurol-2018-002116
21. Ghosh H, Patel R, Woodward E, et al. Contemporary Molecular Landscape, Survival, and Prognostic Factors in Over 4,000 Gliomas. Neuro Oncol. 2023. doi:10.1093/neuonc/noad179.0642
22. Tesileanu CMS, Dirven L, Wijnenga M, et al. Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV. Neuro Oncol. 2019. doi:10.1093/neuonc/noz200
23. Fan X, Yang M, Zhang X, Li H, Wan X, Liu Y, et al. Mutation profiling of gliomas based on sex, age, and family history. J Clin Oncol. 2023. doi:10.1200/jco.2023.41.16_suppl.e14041
24. Lim-Fat M, Vogelzang J, Woodward EL, et al. A multi-institutional comparative analysis of IDH-mutant gliomas across age groups. Neuro Oncol. 2020. doi:10.1093/neuonc/noaa215.329
25. Shen G, Wang R, Gao B, Zhang Z, Wu G, Pope W. MRI features and prognosis of gliomas associated with IDH1 mutation. Front Oncol. 2020. doi:10.3389/fonc.2020.00852
26. Jones P, Carroll KT, Koch M, et al. Isocitrate dehydrogenase mutations in low-grade gliomas correlate with prolonged survival in older patients. Neurosurgery. 2019. doi:10.1093/neuros/nyy149
27. Park Y, Park J, Ahn J, et al. Transcriptomic landscape of lower grade glioma based on age-related non-silent somatic mutations. Curr Oncol. 2021; 28(3): 210. doi:10.3390/curroncol28030210
28. Kayabolen A, Yilmaz E, Bagci-Onder T. IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications? Biomedicines. 2021. doi:10.3390/biomedicines9070799
29. Richardson LG, et al. Implications of IDH Mutations on Immunotherapeutic Strategies for Malignant Glioma. Neurosurg Focus. 2022. doi:10.3171/2021.11.FOCUS21604
30. Pirozzi CJ, Yan H. The Implications of IDH Mutations for Cancer Development and Therapy. Nat Rev Clin Oncol. 2021. doi:10.1038/s41571-021-00521-0
31. Yuile A, et al. Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Glioma. Curr Issues Mol Biol. 2022; 44(10): 348. doi:10.3390/cimb44100348
32. Nunno VD, et al. Non-Canonical IDH1 and IDH2 Mutations Are Associated with Improved Survival in Gliomas. Neuro Oncol. 2021. doi:10.1093/neuonc/noab196.467